The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
RecruitingOBSERVATIONAL
Enrollment
40
Participants
Timeline
Start Date
December 3, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Conditions
Hepatocellular Carcinoma (HCC)
Trial Locations (1)
Unknown
RECRUITING
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT06746194 - The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy | Biotech Hunter | Biotech Hunter